The financials
Medpace Holdings, Inc. by the numbers
Medpace Holdings, Inc. (MEDP) reported revenue of $707M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $121M (17% of revenue). For the full year FY2025, revenue was $2.53B (+20% year on year) and net income $451M. Its largest product in Q2 2026 was Metabolic at $219M, 31% of the disclosed total, just ahead of Oncology at 30%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $707M | $603M | +17% |
| Gross profit | $202M | $180M | +12% |
| Operating income | $147M | $126M | +16% |
| Net income | $121M | $90M | +34% |
| Diluted EPS | $4.25 | $3.10 | +37% |
| Product | Revenue | Share |
|---|---|---|
| Metabolic | $219M | 31% |
| Oncology | $209M | 30% |
| Other | $98M | 14% |
| Central Nervous System | $83M | 12% |
| Cardiology | $60M | 8.5% |
| Antiviral And Anti Infective | $38M | 5.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $707.3M (+0.10%)
Metabolic grew +48% year on yearOther -17% year on year
Segment Latestquarter on quarteryear on year
- Metabolic$219.1M$219.1MQoQ -7.8%year on year +48%-7.8%+48%
- Oncology$209.4M$209.4MQoQ +4.0%year on year +11%+4.0%+11%
- Other$98.3M$98.3MQoQ +5.3%year on year -17%+5.3%-17%
- Central Nervous System$82.9M$82.9MQoQ +3.3%year on year +36%+3.3%+36%
- Cardiology$60.0M$60.0MQoQ +6.6%year on year +2.4%+6.6%+2.4%
- Antiviral And Anti Infective$37.8M$37.8MQoQ -0.65%year on year +30%-0.65%+30%
Diagnostics & Research
Ranks #10 of 17 by Smart Score